DIPHOSPHONATE MK-217 FOR PREVENTION OF BONE LOSS DURING EARLY MENOPAUSE

二磷酸盐 MK-217 用于预防绝经早期骨质流失

• 批准号: 3852399
• 负责人: ELLEN W SEELY
• 金额: --
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3852399
• 关键词: arm; diphosphonate; disease /disorder prevention /control; drug administration rate /duration; drug adverse effect; drug screening /evaluation; female; hip; human subject; human therapy evaluation; menopause; oral administration; pathologic bone resorption; placebos; skeletal disorder chemotherapy; spine

This is a randomized, placebo-controlled dose ranging study to evaluate the safety and efficacy of the new oral diphophonate MK-217 when given to early postmenopausal women. The hypothesis to be tested is that daily oral administration of MK-217 will prevent bone loss in the spine, hip and forearm when compared to placebo-treated control.

这是一项随机、安慰剂控制的剂量范围研究